Fertility and Infertility Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Reprod Biol Endocrinol. 2021 Apr 23;19(1):61. doi: 10.1186/s12958-021-00741-0.
Poor ovarian response to gonadotropin is a significant challenge in assisted reproductive technique (ART) and affect 9-24% of ART cycles. This study aimed to evaluate the effect of Myo-inositol on fertility rates in poor ovarian responder women undergoing assisted reproductive technique.
This study is a double-blinded randomized controlled study that involved 60 poor ovarian responders included in an ICSI program and divided into two groups; intervention group: 30 patients who have been assuming Inofolic (4 g myo-inositol + 400 μg folic acid) for the before the enrollment day; control group: 30 patients assuming folic acid (400 μg) for the same period. Controlled ovarian stimulation was performed in the same manner in the two groups. The main outcomeswere the assessment of oocytes retrievednumber and quality, ovarian sensitivity index,required dose of Gonadotropinsunits × 1000), fertilization rate, biochemical, and clinical pregnancy rate.
There is no significant difference in clinical characteristics between study groups. The number of oocytes retrieved, number of MII oocytes, number of embryos transferred, chemical, and clinical pregnancy were higher in the intervention group. However, they are not statistically significant in comparison to the control group. The ovarian sensitivity index and fertilization rate were significantly higher in the intervention group than the control group (P > 0.05). The required dose of gonadotropin significantly lower in the intervention group than the control group.
Our results suggest that the supplementation myo-inositol in poor ovarian responders significantly improved the ART outcomes such as fertilization rate gonadotropin, ovarian sensitivity index (OSI) and significantly reduced the required unities of gonadotropin. Additionally, more extensive randomized controlled studies are needed.
Iranian Registry of Clinical Trials, IRCT20180515039668N1 , retrospectively registered since 2020-03-16.
卵巢反应不良是辅助生殖技术（ART）中的一个重大挑战，影响 9-24%的 ART 周期。本研究旨在评估肌醇对接受辅助生殖技术的卵巢反应不良患者的生育力的影响。
这是一项双盲随机对照研究，纳入了 60 名接受 ICSI 方案的卵巢反应不良患者，并分为两组；干预组：30 名患者在入组前一天开始服用 Inofolic（4g 肌醇+400μg 叶酸）；对照组：30 名患者在同一时期服用叶酸（400μg）。两组均采用相同的控制性卵巢刺激。主要结局为评估获卵数和质量、卵巢敏感指数、所需的促性腺激素剂量（单位×1000）、受精率、生化和临床妊娠率。
两组的临床特征无显著差异。干预组的获卵数、MII 卵数、可移植胚胎数、生化妊娠和临床妊娠均较高，但与对照组相比无统计学意义。干预组的卵巢敏感指数和受精率明显高于对照组（P>0.05）。干预组所需的促性腺激素剂量明显低于对照组。
我们的结果表明，肌醇补充剂可显著改善卵巢反应不良患者的 ART 结局，如受精率、促性腺激素、卵巢敏感指数（OSI），并显著降低所需的促性腺激素单位数。此外，还需要进行更多的大规模随机对照研究。
伊朗临床试验注册中心，IRCT20180515039668N1 ，自 2020 年 3 月 16 日起回顾性注册。
